Recent Publications: 2002-2007: MJ Duffy

  1. Duffy MJ, Van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. EJC 2007;43:1348-1360.
  2. Culleton J, O’Brien N, Ryan BM, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Lipophilin B: a gene preferentially expressed in breast tissue and upregulated in breast cancer. Int J Cancer 2007;120:1087-1092.
  3. Duffy MJ. Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med 2007;18:175-184.
  4. Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, and Ryan BM. Survivin: a promising tumor biomarker. Cancer Letters 2007;249;49-60.
  5. Lau TYK, Brennan DJ, Duffy MJ, Pennington SR, and Gallagher WM. Breast cancer proteomics: clinical perspectives. Expert Opinion in Biological Therapy 2007;7:209-219.
  6. McGowan PM, Ryan BM, Hill ADK, McDermott, O’Higgins N, Duffy MJ. ADAM-17 expression in breast cancer correlates with parameters of tumor progression. Clin Cancer Res 2007;13:2335-2343.
  7. O’Brien SL, Fagan A, Fox EJ, Milikan RC, Culhane AC, Brennan DJ, McCann A, Hegarty S, Moyna S, Duffy MJ, Higgins DG, Jirstrom K, Landberg G, Gallagher WM. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007;120:1434-43.
  8. Ryan B, Konecny G, Kahlert S, Wang H, Crown J, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. Survivin expression in breast cancer predicts clinical outcome and is associated with HER-2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol, 2006;17:597-604.
  9. Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewska S, Strongin AY. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with survival of breast cancer patients. Cancer Res 2006;66:2716-2714.
  10. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value. Clin Chem 2006;52:345-351.
  11. Buggy Y, Maguire TM, McDermott, E, Hill ADK. O’Higgins N, Duffy MJ. Ets2 transcriptional factor in normal and neoplastic human breast tissue. Eur J Cancer 2006;42:485-491.
  12. Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci. 2006;43:325-47. (Invited Review)
  13. O’Brien N, O’Donovan N, Ryan B, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Mammaglobin a in breast cancer: existence of multiple molecular forms. Int J Cancer 2005;114:623
  14. Duffy MJ. Predictive markers in breast and other cancers. Clin Chem 2005;51:494-503.
  15. Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-deltaEx3 in breast cancer. Br J Cancer 2005;92:120-124.
  16. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick P, Price C, Rimmer J, Sturgeon C, White P, Allen N. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-399.
  17. Brennan D, O’Brien S, Fagan A, Culhane AC, Higgins DG, Duffy MJ, Gallagher WM. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 2005;5:1069-1083. (Invited Review)
  18. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJS, Soletormos G, Torre GC, Tuxen M, Zwirner M. CA 125 in ovarian cancer: Eupopean Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-691.
  19. Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed J, Krajewski S. Tumor associated alterations in caspase14 expression in epithelial malignancies. Clin Cancer Res 2005;11:5462-5471.
  20. Kelly L, Buggy Y, Hill A, O’Donovan N, Duggan C, McDermott E, O’Higgins N, Young L, Duffy MJ. Expression of the breast cancer suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumor Biol 2005;26:213-216.
  21. Duffy MJ, Kelly Z, Culhane AC, O’Brien SL, Gallagher W. DNA microarray-based gene expression profiling in cancer: aiding cancer diagnosis, assessing prognosis and predicting response to therapy. Current Pharmacogenomics 2005;2:289-304.
  22. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G, Stieber P. Tumor markers in breast cancer: European Group on Tumor Markers Recommendations. Tumor Biol 2005;26:281-293.
  23. Duffy MJ, Duggan C, Keane R, Hill ADK, McDermott E, Crown J, Duffy MJ. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004;50:559-563.
  24. Troy AM, Sheahen K, Mulcahy HE, Duffy MJ, Hyland JMP, O’Donoghue DP. Expression of cathepsin B and L antigen and activity is associated with early colorectal progression. Eur J Cancer 2004;40:1610-1616.
  25. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumor markers for the individualized management of patients with breast cancer. Clin Biochem 2004;37:541-548.
  26. Duffy MJ. Evidence for the clinical use of tumor markers. Ann Clin Biochem 2004;41:370-37. (Invited Review)
  27. Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O’Higgins N, Duffy MJ. Overexpression of the ets-1 transcription factor in breast cancer. Br J Cancer 2004;91:1308-1315.
  28. O’Donovan N, Crown J, Stunell H, Hill A, McDermott E, O’Higgins N, Duffy MJ. Caspase 3 in breast cancer. Clin Cancer Res 2003;9:783-742.
  29. Duffy MJ, van Dalen A, Haglund L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O. Clinical Utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) Guidelines. Eur J Cancer 2003;39:718.
  30. Look M, van Putten W, Duffy MJ, plus 36 other authors. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003;90:538.
  31. O’Shea C, McKie N, Buggy Y, Duggan C, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105:754.
  32. Greene LM, Twal WO, Duffy MJ, McDermott E, Hill AD, O’Higgins, N, McCann A, Dervan PA, Argraves WS, Gallagher W. Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 2003;88:871.
  33. Maguire T, Chin D, Soutar D, Duffy MJ. Low Levels of Urokinase Plasminogen Activator in Basal Cell Carcinoma of the Skin. Int J Cancer. 2000;85:457.
  34. Duffy MJ, Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful ?. Clin Chem 2001;47:624-630.
  35. Cullen R, Maguire T, McDermott E, Hill A, O’Higgins N, Duffy MJ. Studies on Oestrogen Receptor-a and -b in Breast Cancer. Eur J Cancer. 2001;37:1118.
  36. Duffy MJ. Clinical uses of tumor markers. Crit Rev Clin Lab Sci 2001;38:225 (Invited review)
  37. Look M, van Putten W, Duffy MJ, Harbeck N, Christensen I, Thomssen C plus 33 other authors. Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and its Inhibitor PAI-1 in 8377 Breast Cancer Patients. J Natl Cancer Instit 2002;94:116. (This is a seminal publication, ie, is one of the very few reports in the literature describing a level 1 evidence study to validate the clinical value of a tumor marker) 
  38. O’Brien N, Maguire TM, O’Donovan N, Lynch N, Hill A, McDermott E, O’Higgins N, Duffy MJ. Mammaglobin A: a Promising Marker for Breast Cancer. Clin Chem 2002;48:1362.
  39. Duffy MJ. Urokinase plasminogen activator and its inhibitor PAI-1 as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-1197 (Invited review).